

BLOOD CANCER OXR - FINAL REPORT

Patient Information

Identification Data		General Biochemistry		Blood Drawn Realization	
HRN:	BRE00000273	Creatinine (mg/dL):	1.00	Blood Drawn Date:	25-01-2020
Name:	Maria Khan	ASAT (U/L):	8.00		
		ALAT (U/L):	12.00	Urine Tumor Market	ers
Personal Data		GGT (U/L):	7.00	8-OHdG (ng/mL):	11.10
Age (years):	23	Total Bilirubin (mg/dL):	1.00		
		Hemolized Sample:	No	Urine Drawn Realization	
Comorbidities				Urine Drawn Date:	25-01-2020
Atherosclerosis: No		Serum Tumor Markers			
Chronic Liver Disease: Yes		CA 15.3 (U/mL):	19.70	Lifestyle	
Diabetes Mellitus 1 or 2: No		CEA (ng/mL):	1.60	Smoking:	Negative
Jaundice: No		EGFR (ng/mL):	5.00		
Renal Failure:	Yes	NGAL (ng/mL):	4.60		
		NSE (ng/mL):	7.00		

Outcome

Results

Some Tumor Markers are outside the reference range and suggest malignancy.

"High"

Range: Low, Moderate, High

Comments

In absence of comorbidities that are well-known source of False Positive (FP) in healthy patients by increasing some Tumor Markers levels, whole Tumor Markers levels suggest malignancy.

Conclusions

WE SUGGEST BLOOD CANCER. THE 2016 ICD-10-CM DIAGNOSIS CODE IS C50 (MALIGNANT NEOPLASM OF BLOOD).

This report has been generated from the data entered on 25-01-2020 10:55:02 UTC/GMT.

Disclaimer

This Multiple Biomarkers Disease Activity Algorithm (MBDAA) for Blood Cancer has been developed for the exclusive use by healthcare professionals, and solely as a Clinical Decision Support System (CDSS), not as an unique element for diagnosis. The algorithm bears a Sensitivity = 82.3%, Specificity = 85.7%. Please note, negativity of the Tumor Markers does not exclude at 100% the possibility of a malignant epithelial tumor.

The Royal London Hospital,

London

Email: friendsrlh.com

Website: www.friendsoftheroyallondonhospital.org.uk



Technical Responsible
Lorena Lendinez
Chief Scientific Officer

The Royal London Hospital